Same-day shipping on orders placed before 2 PM CT
CatalogCalculatorResearchAboutSupport
CatalogCalculatorResearchAboutSupport
Back to Research
Research & Science · 6 min read

TB-500 and Thymosin Beta-4: What the Repair-Peptide Research Actually Shows

Where TB-500 comes from

TB-500 is a synthetic peptide built around the active region of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein that occurs naturally in nearly every cell and at especially high levels in platelets and wound fluid. Tβ4's job in the body is mundane and important: it binds monomeric (G-) actin and helps regulate the balance between free actin and the polymerized filaments (F-actin) that cells use to change shape and move. TB-500 reproduces the short sequence responsible for that actin-binding behavior.

That single mechanism is the thread tying together everything the peptide is studied for. If you make it easier for cells to remodel their actin scaffolding, you make it easier for them to migrate, and migration is the first step in closing a wound, growing a new capillary, or repopulating injured tissue.

The mechanisms under study

In published preclinical work, Tβ4 and its fragments are examined for:

  • Cell migration into injured tissue, the direct consequence of actin regulation
  • Angiogenesis, the formation of new blood vessels
  • Down-regulation of inflammatory cytokines and chemokines
  • Reduced apoptosis (programmed cell death) in stressed tissue

What actually reached human trials

This is where it pays to be precise. The compound that has been through registered human clinical trials is Thymosin Beta-4 itself, developed by RegeneRx under designations like RGN-259 (an eye-drop formulation studied for dry eye and corneal wound healing) and RGN-352 (an injectable studied in cardiac and neurological repair contexts). The broad multi-tissue evidence base behind those programs is summarized in a review of the animal work (Philp & Kleinman, *Ann N Y Acad Sci* 2010), and the ophthalmic line has appeared in registered clinical studies.

"TB-500" as sold in research channels is the synthetic fragment, not the full-length protein used in those trials, a distinction worth keeping in view when reading across the literature.

An honest read

Outside the specific Tβ4 ophthalmic and cardiac programs, the great majority of TB-500 data is animal-model and in-vitro research. The actin-binding mechanism is well established at the molecular level; the leap from "promotes cell migration in a rat tendon" to any broader claim is exactly the leap the published evidence has not yet made. Treat it as a mechanistically interesting compound with a thin human dataset.

Supplied lyophilized for laboratory research use only. Not for human or animal consumption.

References

  1. Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. *Ann N Y Acad Sci.* 2010;1194:81–86. PubMed
  2. Registered clinical studies of thymosin beta-4 (RGN-259). PubMed search